17,261 trials
Kidney Failure, Chronic
Primary: Change From Baseline in Serum Phosphorus at Day 22 (Genz-644470 vs Placebo) — -0.0; -0.6; -1.2; -1.8 mg/dL — p=0.0249
Sarcoma
Primary: Tumor Response — 10 participants
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants
Nicotine Dependence
Primary: Cigarette Choice — 3.67; 3.17; 2.83; 2.83 number of cigarette choices (0-9)
Gastric Cancer
Primary: Progression Free Survival (PFS) in the Overall Study Population — 3.91; 3.55 months
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…
Friedreich Ataxia
Primary: Change in Whole Blood Frataxin Levels — -1.5 percentage of baseline frataxin level — p=0.027
Lung Adenocarcinoma
Primary: The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks — 500; 500; 500 mg/m2 of CETUXIMAB
Chorioamnionitis · Brain Injury
Primary: NAC Terminal Elimination Half-life — 1.2; 7.5; 5.1 hours
Acute Pain
Primary: Summed Pain Intensity Differences Over 24 Hours (SPID 0-24) Following the Initial Administration of Study Drug — -52.08; -292.7 units on a scale * hours — p=<0.05
Branch Retinal Vein Occlusion · Central Retinal Vein Occlusion · Macular Edema
Primary: Mean Change From Baseline BCVA — 14; 5 Letters (ETDRS chart)
Atypical Hemolytic-Uremic Syndrome
Primary: Proportion of Patients With Complete TMA Response — 63.6 Percentage of Participants
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST — 0 patients
Sciatica
Primary: Oswestry Disability Index, v2 — -19.0; -13.3 units on a scale
Lung Cancer
Primary: Number CT- Detected Lung Nodules by Participant — 12; 14; 26; 19 lung nodules